Advancements in Bladder Cancer Treatment Revolutionize Standard of Care

The combination of Seagen and Astellas Pharma's Padcev with Merck's Keytruda has been hailed as the "new standard of care" in first-line bladder cancer, according to confirmatory trial data presented at the European Society for Medical Oncology (ESMO) conference. The combination therapy demonstrated significantly improved overall survival and progression-free survival compared to chemotherapy, potentially expanding the eligible patient population.